Clinical Course: Progression, Management, and Treatment
Clinical considerations for care of children and adults with confirmed COVID-19
‹ View Table of Contents
- The clinical spectrum of SARS-CoV-2 infection includes asymptomatic infection and mild, moderate, severe, and critical illness.
- Information about clinical management and treatment of COVID-19 is categorized by severity of illness.
- Most patients with mild or moderate COVID-19 can be managed in an outpatient setting.
- Most patients with severe or critical COVID-19 require hospitalization.
Mild to Moderate Illness
Most patients with COVID-19 experience asymptomatic, or mild to moderate illness that can be managed in the outpatient setting.
Patients without risk factors for severe COVID-19 may benefit from supportive care and symptomatic treatment, including antipyretics, analgesics, and antitussives. Patients can also be instructed on preventing SARS-CoV-2 transmission and reducing COVID-19 symptoms that indicate the need for additional medical attention.
Some patients with mild to moderate COVID-19 may be at increased risk for progression to severe COVID-19. For these patients, therapeutics, such as antivirals, have been shown to significantly decrease the risk of hospitalization and death. The reductions in severe outcomes from antivirals are documented despite emergence of variants. Patient outcomes are improved if therapeutics are started within the first 5-7 days of illness. (12, 14-21) Test to treat may allow for timely diagnosis and treatment of patients who are at risk for severe illness. The Home Test to Treat program will end April 16, 2024, for all participants. Clinicians should consider offering therapeutics and closely monitoring patients with risk factors for severe illness.
Pulse oximetry has been used to monitor oxygenation in the ambulatory setting, but pulse oximeters may not detect occult hypoxemia in all patients, especially in those who have darker skin, and smart phone-based pulse oximeters may not be able to accurately detect hypoxia (22, 23). Clinicians caring for patients with dyspnea should consider close monitoring with pulse oximeters because of the risk for progression to acute respiratory distress syndrome (ARDS).
The Infectious Disease Society of America (IDSA) recommend Nirmatrelvir with ritonavir (Paxlovid) and Remdesivir (Veklury) for treatment of mild-to-moderate COVID-19 in people at risk for severe illness.
- Remdesivir (Veklury) – The FDA has approved this intravenous antiviral medication for the treatment of COVID-19 in adults and pediatric patients.
- Nirmatrelvir with ritonavir (Paxlovid) – The FDA has approved this oral antiviral for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe illness. Nirmatrelvir-ritonavir (Paxlovid) is manufactured and packaged under the emergency use authorization (EUA) and distributed by the U.S. Department of Health and Human Services and will continue to be available to ensure continued access to treatment for adults, as well as treatment of eligible children ages 12-18 years, who are not covered by the approval. For more information about nirmatrelvir-ritonavir (Paxlovid), please see the FDA Fact Sheet for Healthcare Providers and the approved label [5 MB, 51 pages].
Molnupiravir is recommended as a second-line or alternative option for those unable to receive Remdesivir or Nirmatrelvir with ritonavir.
- Molnupiravir (Lagevrio) – FDA has issued an emergency use authorization (EUA) for molnupiravir, an oral antiviral which can be used for treatment of patients with mild to moderate illness who are at risk for progression to severe illness.
Clinicians should refer to the Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 for up-to-date recommendations regarding eligibility, effectiveness of therapeutics, rationale for treatment of sub-populations, specific drug classes, general management, and therapeutic management.
The FDA has issued an EUA to permit the emergency use of COVID-19 convalescent plasma with high titers of anti-SARS-CoV-2 antibodies for the treatment of COVID-19 in patients with immunosuppressive disease or receiving immunosuppressive treatment, in either the outpatient or inpatient setting. For more information, please see the FDA Fact Sheet for Providers. Please also see Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19, which provide recommendations on who should be considered for this treatment.
Severe to Critical Illness
Severe illness related to COVID-19 is defined as having oxygen saturation <94% on room air at sea level, a ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2) <300 mm Hg, a respiratory rate >30 breaths/min, lung infiltrates >50%, or requiring invasive mechanical ventilation.
In adults, older age (especially ages 65 and over) is the strongest risk factor for severe COVID-19 illness and risk increases with increasing age.(1–2) People aged 65 and older should receive 1 dose of an updated COVID-19 vaccine should receive 1 additional dose of an updated vaccine. Certain underlying medical conditions are also associated with increased risk of severe COVID-19, and the risk of hospitalization, ICU admission, and death increases as the number of high-risk underlying conditions increases.(2–4) COVID-19 vaccination remains the best protection against COVID-19-associated hospitalization and death, including providing sustained protection against COVID-19-associated critical illness and death. Vaccination also reduces the chance of suffering the effects of Long COVID, which can develop during or following acute infection and last for an extended duration.
The COVID-19 pandemic highlighted racial, ethnic, and socioeconomic disparities in COVID-19 illnesses, hospitalizations, and deaths.(4-6) Studies have identified racial and ethnic differences in at-home COVID-19 test use, vaccination coverage, and access to outpatient therapeutics.(7-9) Studies also show that COVID-19 vaccination coverage is lower in rural counties than in urban counties, and from 2020 to 2022, the United States experienced higher COVID-19 incidence and mortality rates in rural than in urban areas.(10,11)
Clinical treatment recommendations for people with severe to critical COVID-19 are based on the severity of illness. Management often includes care of complications of severe illness, including:
- hypoxemic respiratory failure/ARDS,
- sepsis and septic shock,
- elevation in inflammatory cytokines,
- and complications from prolonged hospitalization, including thromboembolism, hospital-acquired pneumonia, and hospital-acquired bacterial and fungal infections.
Additionally, patients with COVID-19 may experience an exacerbation of underlying comorbidities or new onset of cardiac, endocrine, hepatic, renal, gastrointestinal, or central nervous system disease.
The FDA has authorized or approved the use of several medications for patients with severe or critical illness due to COVID-19. Clinicians can find general considerations and recommendations for the care of critically ill patients along with the rationale for the recommendations in the Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Research for effective treatments for COVID-19 is ongoing, and more information about clinical trials can be found at ClinicalTrials.gov.
- COVID-19 Test to Treat Locators
- Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19
- Paxlovid™ Drug-Drug Interactions
- COVID-19 Therapeutics Decision Aid
- Side-by-Side Overview of Therapeutics
- Outpatient COVID-19 Therapeutics Administration Guide for Healthcare Providers
- Key Points
- Clinical Presentation
- › Clinical Progression, Management, and Treatment
- Special Clinical Considerations
References
- Bhaskaran K, Bacon S, Evans SJ, et al. Factors associated with deaths due to COVID-19 versus other causes: population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform. Lancet Reg Health Eur. Jul 2021;6:100109. doi:10.1016/j.lanepe.2021.100109
- Kim L, Garg S, O'Halloran A, et al. Risk Factors for Intensive Care Unit Admission and In-hospital Mortality among Hospitalized Adults Identified through the U.S. Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET). Clin Infect Dis. Jul 16 2020;doi:10.1093/cid/ciaa1012
- Kompaniyets L, Pennington AF, Goodman AB, et al. Underlying Medical Conditions and Severe Illness Among 540,667 Adults Hospitalized With COVID-19, March 2020-March 2021. Preventing chronic disease. Jul 1 2021;18:E66. doi:10.5888/pcd18.210123
- Ko JY, Danielson ML, Town M, et al. Risk Factors for COVID-19-associated hospitalization: COVID-19-Associated Hospitalization Surveillance Network and Behavioral Risk Factor Surveillance System. Clin Infect Dis. Sep 18 2020;doi:10.1093/cid/ciaa1419
- Wortham JM, Lee JT, Althomsons S, et al. Characteristics of Persons Who Died with COVID-19 - United States, February 12-May 18, 2020. MMWR Morb Mortal Wkly Rep. Jul 17 2020;69(28):923-929. doi:10.15585/mmwr.mm6928e1
- Yang X, Zhang J, Chen S, et al. Demographic Disparities in Clinical Outcomes of COVID-19: Data From a Statewide Cohort in South Carolina. Open Forum Infect Dis. Sep 2021;8(9):ofab428. doi:10.1093/ofid/ofab428
- Rader B.; Gertz AL, D.; Gilmer, M.; Wronski, L.; Astley, C.; Sewalk, K.; Varrelman, T.; Cohen, J.; Parikh, R.; Reese, H.; Reed, C.; Brownstein J. Use of At-Home COVID-19 Tests — United States, August 23, 2021–March 12, 2022. MMWR Morb Mortal Wkly Rep. April 1, 2022;71(13):489–494. doi:http://dx.doi.org/10.15585/mmwr.mm7113e1
- Pingali C, Meghani M, Razzaghi H, et al. COVID-19 Vaccination Coverage Among Insured Persons Aged >/=16 Years, by Race/Ethnicity and Other Selected Characteristics - Eight Integrated Health Care Organizations, United States, December 14, 2020-May 15, 2021. MMWR Morb Mortal Wkly Rep. Jul 16 2021;70(28):985-990. doi:10.15585/mmwr.mm7028a1
- Wiltz JL, Feehan AK, Molinari NM, et al. Racial and Ethnic Disparities in Receipt of Medications for Treatment of COVID-19 - United States, March 2020-August 2021. MMWR Morb Mortal Wkly Rep. Jan 21 2022;71(3):96-102. doi:10.15585/mmwr.mm7103e1
- Murthy NC, Zell E, Fast HE, et al. Disparities in First Dose COVID-19 Vaccination Coverage among Children 5-11 Years of Age, United States. Emerg Infect Dis. May 2022;28(5):986-989. doi:10.3201/eid2805.220166
- Saelee R, Zell E, Murthy BP, et al. Disparities in COVID-19 Vaccination Coverage Between Urban and Rural Counties - United States, December 14, 2020-January 31, 2022. MMWR Morb Mortal Wkly Rep. Mar 4 2022;71(9):335-340. doi:10.15585/mmwr.mm7109a2
- Burki TK. The role of antiviral treatment in the COVID-19 pandemic. Lancet Respir Med. Feb 2022;10(2):e18. doi:10.1016/S2213-2600(22)00011-X
- Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. N Engl J Med. Feb 10 2022;386(6):509-520. doi:10.1056/NEJMoa2116044
- Bai Y, Du Z, Wang L, et al. Public Health Impact of Paxlovid as Treatment for COVID-19, United States. Emerg Infect Dis 2024;30(2) (In eng). DOI: 10.3201/eid3002.230835.
- Najjar-Debbiny R, Gronich N, Weber G, et al. Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients. Clin Infect Dis 2023;76(3):e342-e349. (In eng). DOI: 10.1093/cid/ciac443.
- Shah MM, Joyce B, Plumb ID, et al. Paxlovid Associated with Decreased Hospitalization Rate Among Adults with COVID-19 - United States, April-September 2022. MMWR Morb Mortal Wkly Rep 2022;71(48):1531-1537. (In eng). DOI: 10.15585/mmwr.mm7148e2.
- Dryden-Peterson S, Kim A, Kim AY, et al. Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large U.S. Health System : A Population-Based Cohort Study. Ann Intern Med 2023;176(1):77-84. (In eng). DOI: 10.7326/m22-2141.
- Lewnard JA, McLaughlin JM, Malden D, et al. Effectiveness of nirmatrelvir-ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system. Lancet Infect Dis 2023;23(7):806-815. (In eng). DOI: 10.1016/s1473-3099(23)00118-4.
- Hammond J, Leister-Tebbe H, Gardner A, et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. N Engl J Med 2022;386(15):1397-1408. (In eng). DOI: 10.1056/NEJMoa2118542.
- Arbel R, Wolff Sagy Y, Hoshen M, et al. Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge. N Engl J Med 2022;387(9):790-798. (In eng). DOI: 10.1056/NEJMoa2204919.
- Skarbinski J, Wood M, Chervo T, et al. Risk of severe clinical outcomes among persons with SARS-CoV-2 infection with differing levels of vaccination during widespread Omicron (B.1.1.529) and Delta (B.1.617.2) variant circulation in Northern California: A retrospective cohort study. Lancet Reg Health Am 2022;12:100297. https://dx.doi.org/10.1016/j.lan.
- Sjoding MW, Dickson RP, Iwashyna TJ, Gay SE, Valley TS. Racial Bias in Pulse Oximetry Measurement. N Engl J Med. Dec 17 2020;383(25):2477-2478. doi:10.1056/NEJMc2029240
- Jordan TB, Meyers CL, Schrading WA, Donnelly JP. The utility of iPhone oximetry apps: A comparison with standard pulse oximetry measurement in the emergency department. Am J Emerg Med. May 2020;38(5):925-928. doi:10.1016/j.ajem.2019.07.020
- Iuliano AD, Brunkard JM, Boehmer TK, et al. Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods - United States, December 2020-January 2022. MMWR Morb Mortal Wkly Rep. Jan 28 2022;71(4):146-152. doi:10.15585/mmwr.mm7104e4
- Taylor CA, Whitaker M, Anglin O, et al. COVID-19-Associated Hospitalizations Among Adults During SARS-CoV-2 Delta and Omicron Variant Predominance, by Race/Ethnicity and Vaccination Status - COVID-NET, 14 States, July 2021-January 2022. MMWR Morb Mortal Wkly Rep. Mar 25 2022;71(12):466-473. doi:10.15585/mmwr.mm7112e2
- Johnson AG, Amin AB, Ali AR, et al. COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence - 25 U.S. Jurisdictions, April 4-December 25, 2021. MMWR Morb Mortal Wkly Rep. Jan 28 2022;71(4):132-138. doi:10.15585/mmwr.mm7104e2
- Danza P, Koo TH, Haddix M, et al. SARS-CoV-2 Infection and Hospitalization Among Adults Aged >/=18 Years, by Vaccination Status, Before and During SARS-CoV-2 B.1.1.529 (Omicron) Variant Predominance - Los Angeles County, California, November 7, 2021-January 8, 2022. MMWR Morb Mortal Wkly Rep. Feb 4 2022;71(5):177-181. doi:10.15585/mmwr.mm7105e1